TAK - Takeda Pharmaceutical Non-GAAP EPS of ¥558.00 revenue of ¥4.03B; initiates FY23 guidance

2023-05-11 03:31:04 ET

• Takeda Pharmaceutical press release ( NYSE: TAK ): FY Non-GAAP EPS of ¥558.00.
• Revenue of ¥4.03B growth of +12.8%; Core Revenue Growth of +3.5% at Constant Exchange Rate Driven by Growth & Launch Products;
• Reported EPS Growth of +38.8%.
• Achieved Core Operating Profit of ¥1,188.4B.
• Outlook: FY2023 Core Operating Profit Expected to Remain >1 Trillion Yen Despite Impact of Loss of Exclusivity and Lower Expectations for Coronavirus Vaccines.
• Expects Core Revenue of ¥3,840.0; Core EPS of ¥434; Core Operating Profit of ¥1,015.0.

• “Strong financial discipline and free cash flow have enabled us to deleverage rapidly while investing in growth. As a result, we are forecasting a dividend increase for the first time in 15 years, from 180 yen to 188 yen per share.

For further details see: